Table of Contents

Chapter 1 Cancer Biopsy Market: Research Methodology And Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Product Segment
1.1.1.2 Type Segment
1.1.1.3 Application Segment
1.1.1.4 End Use Segment
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Gvr’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations
Chapter 2 Cancer Biopsy Market: Executive Summary
2.1 Market Outlook
2.2 Product And Type Snapshot
2.3 Application Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Cancer Biopsy Market: Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Related/Ancillary Market Outlook
3.2 Market Dynamics
3.2.1 Market Drivers Analysis
3.2.1.1 Advent Of Liquid Biopsy
3.2.1.2 Transition Of Novel Oncology Diagnostics From Bench To Clinics
3.2.1.3 Advancements In Quality And Payment Pertaining To Genetic Cancer Tests
3.2.2 Market Restraint Analysis
3.2.2.1 Risks Associated With Biopsy Procedures
3.2.2.2 Technical And Clinical Challenges
3.3 Industry Analysis Tools
3.3.1 Porter’s Analysis
3.3.2 Pestel Analysis
Chapter 4 Cancer Biopsy Market: Product Business Analysis
4.1 Cancer Biopsy Market: Product Movement Analysis
4.2 Instruments
4.2.1 Instruments Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.3 Kits And Consumabkes
4.3.1 Kits And Consumabels Market Estimates And Forecast, 2018 – 2030 (USD Million)
4.4 Services
4.4.1 Services Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 5 Cancer Biopsy Market: Type Business Analysis
5.1 Cancer Biopsy Market: Type Movement Analysis
5.2 Tissue Biopsies
5.2.1 Tissue Biopsies Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.2.2 Needle Biopsies
5.2.2.1 Needle Biopsies Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.2.2.2 Fine Needle Aspiration (Fna)
5.2.2.2.1 Fine Needle Aspiration (Fna) Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.2.2.3 Core Needle Biopsy (Cnb)
5.2.2.3.1 Core Needle Biopsy (Cnb) Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.2.3 Surgical Biopsies
5.2.3.1 Surgical Biopsies Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.3 Liquid Biopsies
5.3.1 Liquid Biopsies Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.4 Others
5.4.1 Others Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 6 Cancer Biopsy Market: Application Business Analysis
6.1 Cancer Biopsy Market: Application Movement Analysis
6.2 Breast Cancer
6.2.1 Breast Cancer Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.3 Colorectal Cancer
6.3.1 Colorectal Cancer Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.4 Cervical Cancers
6.4.1 Cervical Cancers Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.5 Lung Cancers
6.5.1 Lung Cancers Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.6 Prostate Cancers
6.6.1 Prostate Cancers Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.7 Skin Cancers
6.7.1 Skin Cancers Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.8 Blood Cancers
6.8.1 Blood Cancers Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.9 Kidney Cancers
6.9.1 Kidney Cancers Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.10 Liver Cancers
6.10.1 Liver Cancers Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.11 Pancreatic Cancers
6.11.1 Pancreatic Cancers Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.12 Ovarian Cancers
6.12.1 Ovarian Cancers Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.13 Others
6.13.1 Others Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 7 Cancer Biopsy Market: Regional Business Analysis
7.1 Regional Market Snapshot
7.2 North America
7.2.1 North America Cancer Biopsy Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.2.2.2 Key Country Dynamics
7.2.2.3 Regulatory Framework
7.2.2.4 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Canada Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.2.3.2 Key Country Dynamics
7.2.3.3 Regulatory Framework
7.2.3.4 Reimbursement Scenario
7.3 Europe
7.3.1 Europe Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.3.2 Uk
7.3.2.1 Uk Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.3.2.2 Key Country Dynamics
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Germany Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.3.3.2 Key Country Dynamics
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.4 Spain
7.3.4.1 Spain Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.3.4.2 Key Country Dynamics
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.5 France
7.3.5.1 France Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.3.5.2 Key Country Dynamics
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.6 Italy
7.3.6.1 Italy Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.3.6.2 Key Country Dynamics
7.3.6.3 Regulatory Framework
7.3.6.4 Reimbursement Scenario
7.3.7 Denmark
7.3.7.1 Denmark Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.3.7.2 Key Country Dynamics
7.3.7.3 Regulatory Framework
7.3.7.4 Reimbursement Scenario
7.3.8 Sweden
7.3.8.1 Sweden Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.3.8.2 Key Country Dynamics
7.3.8.3 Regulatory Framework
7.3.8.4 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Norway Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.3.9.2 Key Country Dynamics
7.3.9.3 Regulatory Framework
7.3.9.4 Reimbursement Scenario
7.4 Asia Pacific
7.4.1 Asia-Pacific Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.4.2.2 Key Country Dynamics
7.4.2.3 Regulatory Framework
7.4.2.4 Reimbursement Scenario
7.4.3 China
7.4.3.1 China Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.4.3.2 Key Country Dynamics
7.4.3.3 Regulatory Framework
7.4.3.4 Reimbursement Scenario
7.4.4 India
7.4.4.1 India Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.4.4.2 Key Country Dynamics
7.4.4.3 Regulatory Framework
7.4.4.4 Reimbursement Scenario
7.4.5 South Korea
7.4.5.1 South Korea Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.4.5.2 Key Country Dynamics
7.4.5.3 Regulatory Framework
7.4.5.4 Reimbursement Scenario
7.4.6 Thailand
7.4.6.1 Thailand Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.4.6.2 Key Country Dynamics
7.4.6.3 Regulatory Framework
7.4.6.4 Reimbursement Scenario
7.4.7 Australia
7.4.7.1 Australia Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.4.7.2 Key Country Dynamics
7.4.7.3 Regulatory Framework
7.4.7.4 Reimbursement Scenario
7.5 Latin America
7.5.1 Latin America Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.5.2.2 Key Country Dynamics
7.5.2.3 Regulatory Framework
7.5.2.4 Reimbursement Scenario
7.5.3 Mexico
7.5.3.1 Mexico Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.5.3.2 Key Country Dynamics
7.5.3.3 Regulatory Framework
7.5.2.4 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Argentina Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.5.4.2 Key Country Dynamics
7.5.4.3 Regulatory Framework
7.5.4.4 Reimbursement Scenario
7.6 MEA
7.6.1 MEA Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.6.2.2 Key Country Dynamics
7.6.2.3 Regulatory Framework
7.6.2.4 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.6.3.2 Key Country Dynamics
7.6.3.3 Regulatory Framework
7.6.3.4 Reimbursement Scenario
7.6.4 Uae
7.6.4.1 Uae Cancer Biopsy Market, 2018 – 2030 (USD Million)
7.6.4.2 Key Country Dynamics
7.6.4.3 Regulatory Framework
7.6.2.4 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Kuwait Cancer Biopsy Market, 2018 – 2030 (USD MILLION)
7.6.5.2 Key Country Dynamics
7.6.5.3 Regulatory Framework
7.6.5.4 Reimbursement Scenario
Chapter 8 Cancer Biopsy Market: Competitive Landscape
8.1 Company Categorization
8.2 Strategy Mapping
8.2.1 New product launch
8.2.2 Partnerships
8.2.3 Acquisition
8.2.4 Collaboration
8.2.5 Funding
8.3 Company Market Share Analysis, 2022
8.4 Company Profiles
8.4.1 QIAGEN
8.4.1.1 Company overview
8.4.1.2 Financial performance
8.4.1.3 Product benchmarking
8.4.1.4 Strategic initiatives
8.4.2 ILLUMINA, INC.
8.4.2.1 Company overview
8.4.2.2 Financial performance
8.4.2.3 Product benchmarking
8.4.2.4 Strategic initiatives
8.4.3 ANGLE PLC
8.4.3.1 Company overview
8.4.3.2 Financial performance
8.4.3.3 Product benchmarking
8.4.3.4 Strategic initiatives
8.4.4 BD (BECTON, DICKINSON AND COMPANY)
8.4.4.1 Company overview
8.4.4.2 Financial performance
8.4.4.3 Product benchmarking
8.4.4.4 Strategic initiatives
8.4.5 MYRIAD GENETICS
8.4.5.1 Company overview
8.4.5.1.1 Counsyl, Inc.
8.4.5.2 Financial performance
8.4.5.3 Product benchmarking
8.4.5.4 Strategic initiatives
8.4.6 HOLOGIC, INC.
8.4.6.1 Company overview
8.4.6.2 Financial performance
8.4.6.3 Product benchmarking
8.4.7 BIOCEPT, INC.
8.4.7.1 Company overview
8.4.7.2 Financial performance
8.4.7.3 Product benchmarking
8.4.7.4 Strategic initiatives
8.4.8 THERMO FISHER SCIENTIFIC, INC.
8.4.8.1 Company overview
8.4.8.2 Financial performance
8.4.8.3 Product benchmarking
8.4.8.4 Strategic initiatives
9.4.9 DANAHER
8.4.9.1 Company overview
8.4.9.2 Beckman Coulter, Inc
8.4.9.3 Radiometer Medical ApS
8.4.9.4 HemoCue AB
8.4.9.5 Financial performance
8.4.9.6 Product benchmarking
8.4.10 F. HOFFMANN-LA ROCHE LTD.
8.4.10.1 Company overview
8.4.10.2 FOUNDATION MEDICINE, INC.
8.4.10.3 Financial performance
8.4.10.4 Product benchmarking
8.4.11 LUCENCE DIAGNOSTICS PTE. LTD.
8.4.11.1 Company overview
8.4.11.2 Financial performance
8.4.11.3 Product benchmarking
8.4.11.4 Strategic initiatives
8.4.12 GRAIL, INC.
8.4.12.1 Company overview
8.4.12.2 Financial performance
8.4.12.3 Product benchmarking
8.4.12.4 Strategic initiatives
8.4.13 GUARDANT HEALTH
8.4.13.1 Company overview
8.4.13.2 Financial performance
8.4.13.3 Product benchmarking
8.4.13.4 Strategic initiatives
8.4.14 EXACT SCIENCES CORPORATION
8.4.14.1 Company overview
8.4.14.2 Financial performance
8.4.14.3 Product benchmarking
8.4.14.4 Strategic initiatives
8.4.15 FREENOME HOLDINGS, INC.
8.4.15.1 Company overview
8.4.15.2 Financial performance
8.4.15.3 Product benchmarking
8.4.15.4 Strategic initiatives
8.4.16 BIODESIX (INTEGRATED DIAGNOSTICS)
8.4.16.1 Company overview
8.4.16.2 Financial performance
8.4.16.3 Product benchmarking
8.4.16.4 Strategic initiatives
8.4.17 ONCIMMUNE
8.4.17.1 Company overview
8.4.17.2 Financial performance
8.4.17.3 Product benchmarking
8.4.17.4 Strategic initiatives
8.4.18 EPIGENOMICS AG.
8.4.18.1 Company overview
8.4.18.2 Financial performance
8.4.18.3 Product benchmarking
8.4.18.4 Strategic initiatives
8.4.19 HELIOHEALTH (LABORATORY FOR ADVANCED MEDICINE)
8.4.19.1 Company overview
8.4.19.2 Financial performance
8.4.19.3 Product benchmarking
8.4.19.4 Strategic initiatives
8.4.20 GENESYSTEMS, INC. (GENESYS BIOLABS)
8.4.20.1 Company overview
8.4.20.2 Financial performance
8.4.20.3 Product benchmarking
8.4.20.4 Strategic initiatives
8.4.21 CHRONIX BIOMEDICAL, INC.
8.4.21.1 Company overview
8.4.21.2 Financial performance
8.4.21.3 Product benchmarking
8.4.21.4 Strategic initiatives
8.4.22 PERSONAL GENOME DIAGNOSTICS INC.
8.4.22.1 Company overview
8.4.22.2 Financial performance
8.4.22.3 Product benchmarking
8.4.22.4 Strategic initiatives
8.4.23 NATERA, INC.
8.4.23.1 Company overview
8.4.23.2 Financial performance
8.4.23.3 Product benchmarking
8.4.23.4 Strategic initiatives
8.4.24 PERSONALIS INC.
8.4.16.1 Company overview
8.4.24.2 Financial performance
8.4.24.3 Product benchmarking
8.4.24.4 Strategic initiatives
Chapter 9 KOL Recommendations/Analyst Perspective